Andrea Bezjak1, Rebecca Paulus2, Laurie E Gaspar3, Robert D Timmerman4, William L Straube5, William F Ryan6, Yolanda I Garces7, Anthony T Pu8, Anurag K Singh9, Gregory M Videtic10, Ronald C McGarry11, Puneeth Iyengar4, Jason R Pantarotto12, James J Urbanic13, Alexander Y Sun1, Megan E Daly14, Inga S Grills15, Paul Sperduto16, Daniel P Normolle17, Jeffrey D Bradley5, Hak Choy4. 1. 1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada. 2. 2 NRG Oncology, Philadelphia, PA. 3. 3 University of Colorado Denver, Aurora, CO. 4. 4 The University of Texas Southwestern, Dallas, TX. 5. 5 Washington University in St Louis, St Louis, MO. 6. 6 Pocono Medical Center, East Stroudsburg, PA. 7. 7 Mayo Clinic, Rochester, MN. 8. 8 Sutter General Hospital, Sacramento, CA. 9. 9 Roswell Park Cancer Institute, Buffalo, NY. 10. 10 Cleveland Clinic Foundation, Cleveland, OH. 11. 11 University of Kentucky, Lexington, KY. 12. 12 Ottawa Hospital and Cancer Center, Ottawa, Ontario, Canada. 13. 13 University of California, San Diego, La Jolla, CA. 14. 14 University of California, Davis, Davis, CA. 15. 15 William Beaumont Hospital, Royal Oak, MI. 16. 16 Metro-Minnesota Community Clinical Oncology Program, St Louis Park, MN. 17. 17 University of Pittsburgh Medical Center, Pittsburgh, PA.
Abstract
PURPOSE: Patients with centrally located early-stage non-small-cell lung cancer (NSCLC) are at a higher risk of toxicity from high-dose ablative radiotherapy. NRG Oncology/RTOG 0813 was a phase I/II study designed to determine the maximum tolerated dose (MTD), efficacy, and toxicity of stereotactic body radiotherapy (SBRT) for centrally located NSCLC. MATERIALS AND METHODS: Medically inoperable patients with biopsy-proven, positron emission tomography-staged T1 to 2 (≤ 5 cm) N0M0 centrally located NSCLC were accrued into a dose-escalating, five-fraction SBRT schedule that ranged from 10 to 12 Gy/fraction (fx) delivered over 1.5 to 2 weeks. Dose-limiting toxicity (DLT) was defined as any treatment-related grade 3 or worse predefined toxicity that occurred within the first year. MTD was defined as the SBRT dose at which the probability of DLT was closest to 20% without exceeding it. RESULTS: One hundred twenty patients were accrued between February 2009 and September 2013. Patients were elderly, there were slightly more females, and the majority had a performance status of 0 to 1. Most cancers were T1 (65%) and squamous cell (45%). Organs closest to planning target volume/most at risk were the main bronchus and large vessels. Median follow-up was 37.9 months. Five patients experienced DLTs; MTD was 12.0 Gy/fx, which had a probability of a DLT of 7.2% (95% CI, 2.8% to 14.5%). Two-year rates for the 71 evaluable patients in the 11.5 and 12.0 Gy/fx cohorts were local control, 89.4% (90% CI, 81.6% to 97.4%) and 87.9% (90% CI, 78.8% to 97.0%); overall survival, 67.9% (95% CI, 50.4% to 80.3%) and 72.7% (95% CI, 54.1% to 84.8%); and progression-free survival, 52.2% (95% CI, 35.3% to 66.6%) and 54.5% (95% CI, 36.3% to 69.6%), respectively. CONCLUSION: The MTD for this study was 12.0 Gy/fx; it was associated with 7.2% DLTs and high rates of tumor control. Outcomes in this medically inoperable group of mostly elderly patients with comorbidities were comparable with that of patients with peripheral early-stage tumors.
PURPOSE:Patients with centrally located early-stage non-small-cell lung cancer (NSCLC) are at a higher risk of toxicity from high-dose ablative radiotherapy. NRG Oncology/RTOG 0813 was a phase I/II study designed to determine the maximum tolerated dose (MTD), efficacy, and toxicity of stereotactic body radiotherapy (SBRT) for centrally located NSCLC. MATERIALS AND METHODS: Medically inoperable patients with biopsy-proven, positron emission tomography-staged T1 to 2 (≤ 5 cm) N0M0 centrally located NSCLC were accrued into a dose-escalating, five-fraction SBRT schedule that ranged from 10 to 12 Gy/fraction (fx) delivered over 1.5 to 2 weeks. Dose-limiting toxicity (DLT) was defined as any treatment-related grade 3 or worse predefined toxicity that occurred within the first year. MTD was defined as the SBRT dose at which the probability of DLT was closest to 20% without exceeding it. RESULTS: One hundred twenty patients were accrued between February 2009 and September 2013. Patients were elderly, there were slightly more females, and the majority had a performance status of 0 to 1. Most cancers were T1 (65%) and squamous cell (45%). Organs closest to planning target volume/most at risk were the main bronchus and large vessels. Median follow-up was 37.9 months. Five patients experienced DLTs; MTD was 12.0 Gy/fx, which had a probability of a DLT of 7.2% (95% CI, 2.8% to 14.5%). Two-year rates for the 71 evaluable patients in the 11.5 and 12.0 Gy/fx cohorts were local control, 89.4% (90% CI, 81.6% to 97.4%) and 87.9% (90% CI, 78.8% to 97.0%); overall survival, 67.9% (95% CI, 50.4% to 80.3%) and 72.7% (95% CI, 54.1% to 84.8%); and progression-free survival, 52.2% (95% CI, 35.3% to 66.6%) and 54.5% (95% CI, 36.3% to 69.6%), respectively. CONCLUSION: The MTD for this study was 12.0 Gy/fx; it was associated with 7.2% DLTs and high rates of tumor control. Outcomes in this medically inoperable group of mostly elderly patients with comorbidities were comparable with that of patients with peripheral early-stage tumors.
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: David Palma; Otto Visser; Frank J Lagerwaard; Jose Belderbos; Ben J Slotman; Suresh Senan Journal: J Clin Oncol Date: 2010-11-01 Impact factor: 44.544
Authors: Achilles J Fakiris; Ronald C McGarry; Constantin T Yiannoutsos; Lech Papiez; Mark Williams; Mark A Henderson; Robert Timmerman Journal: Int J Radiat Oncol Biol Phys Date: 2009-02-27 Impact factor: 7.038
Authors: Victor S Mangona; Andrew M Aneese; Ovidiu Marina; Richard V Hymas; Dan Ionascu; John M Robertson; Lori J Gallardo; Inga Siiner Grills Journal: Int J Radiat Oncol Biol Phys Date: 2014-10-18 Impact factor: 7.038
Authors: Ankit Modh; Andreas Rimner; Eric Williams; Amanda Foster; Mihir Shah; Weiji Shi; Zhigang Zhang; Daphna Y Gelblum; Kenneth E Rosenzweig; Ellen D Yorke; Andrew Jackson; Abraham J Wu Journal: Int J Radiat Oncol Biol Phys Date: 2014-10-08 Impact factor: 7.038
Authors: Joe Y Chang; Qiao-Qiao Li; Qing-Yong Xu; Pamela K Allen; Neal Rebueno; Daniel R Gomez; Peter Balter; Ritsuko Komaki; Reza Mehran; Stephen G Swisher; Jack A Roth Journal: Int J Radiat Oncol Biol Phys Date: 2014-04-01 Impact factor: 7.038
Authors: D Tiberi; P Vavassis; D Nguyen; M C Guilbert; A Simon-Cloutier; P Dubé; M K Gervais; L Sideris; G Leblanc; T Hijal; M P Dufresne; M Yassa Journal: Curr Oncol Date: 2020-06-01 Impact factor: 3.677
Authors: Chunyu Wang; Andreas Rimner; Daphna Y Gelblum; Rosalind Dick-Godfrey; Dominique McKnight; Danielle Torres; Jessica Flynn; Zhigang Zhang; Baho Sidiqi; Andrew Jackson; Ellen Yorke; Abraham J Wu Journal: Lung Cancer Date: 2020-07-08 Impact factor: 5.705
Authors: Kevin C Jones; Julius Turian; Gage Redler; Gizem Cifter; John Strologas; Alistair Templeton; Damian Bernard; James C H Chu Journal: Phys Med Biol Date: 2020-08-10 Impact factor: 3.609
Authors: Bindu V Manyam; Kyle Verdecchia; Kevin Rogacki; Chandana A Reddy; Tingliang Zhuang; Gregory M M Videtic; Joseph T Azok; Kevin L Stephans Journal: J Radiosurg SBRT Date: 2019